Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared an article on LinkedIn:
“On Clinical Trials Day thrilled to share our American Society of Clinical Oncology, ASCO Education Handbook article free online version.
“Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras”
-
The rare cancer research landscape is rapidly evolving with innovative trial designs and precision medicine approaches.
-
Though rare cancers (<150 cases per million annually) individually uncommon, they collectively represent a significant portion of all cancer diagnoses.
-
Next-gen sequencing has revolutionized this field alongside the development of tumor-agnostic therapies (BRAF/NTRK/RET inhibitors, immunotherapy for MSI-high cancers).
-
Collaborative initiatives & patient centric trials are expanding access.“
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.
Authors: Vivek Subbiah, Megan Othus, Jim Palma, Branko Cuglievan, and Razelle Kurzrock.
You can read the full article on Journal of ASCO Educational Book.
More posts featuring Vivek Subbiah.
